If your desire feels muted, disconnected, or simply gone—you’re not alone, and you’re not broken. Low libido affects millions of women, yet treatment options have historically been limited and often designed without understanding how female sexuality actually works. Today, women have choices: from Addyi, the first FDA-approved daily pill for Hypoactive Sexual Desire Disorder (HSDD), to Libida™, Inner Balance’s on-demand sublingual formulation combining bremelanotide and oxytocin. Understanding how these treatments differ—and which approach aligns with your body and life—can help you reclaim the intimate connection you deserve.
Key Takeaways
- Female desire involves both neurochemical and emotional pathways—Libida™ is the first libido solution combining bremelanotide (dopamine/desire spark) with oxytocin (bonding/connection)
- Libida™ works on-demand within 45-60 minutes, while Addyi requires daily dosing at bedtime and typically 4-8 weeks to show benefits
- Addyi carries an FDA boxed warning against alcohol use; Libida™ offers greater lifestyle flexibility
- Low libido often coexists with hormone imbalance—addressing both neurological desire pathways and hormonal foundation may provide comprehensive relief
- Non-hormonal options like Libida™ can complement hormone therapy for women whose desire remains flat even after hormones are optimized
Libida™ is a brain-based libido booster for women – no hormones, meds, or injections. One dissolvable tablet to bring the spark back, on your terms.
HSA/FSA Eligible •
Free shipping • Cancel anytime
Understanding Low Libido in Women: More Than Just Hormones
Low sexual desire in women is rarely simple. Unlike straightforward blood-flow issues, female sexuality involves a complex interplay of neurochemistry, emotional connection, hormonal status, and relationship dynamics.
Hypoactive Sexual Desire Disorder (HSDD) is characterized by persistently low sexual desire that causes personal distress. It affects an estimated 10% of adult women, making it one of the most common sexual health concerns—yet it remained without FDA-approved treatment options until 2015.
Causes of Decreased Sexual Desire
Low libido can stem from multiple sources:
- Hormonal changes during perimenopause, menopause, postpartum, or conditions like PCOS and endometriosis
- Neurochemical imbalances affecting dopamine, serotonin, and other brain chemicals that drive motivation and arousal
- Emotional disconnection from partners, stress, anxiety, or relationship challenges
- Medications including antidepressants, hormonal contraceptives, and blood pressure medications
- Life circumstances such as fatigue, body image concerns, and competing demands
This multi-faceted nature of female desire explains why treatments targeting only one pathway often produce modest results. The most effective approaches address both the neurochemical spark that initiates desire and the emotional readiness that allows women to fully engage in intimacy.
What Is Addyi (Flibanserin)? A Daily Pill for Desire
Addyi made history in 2015 as the first FDA-approved treatment for HSDD in premenopausal women. The FDA has expanded its approval to include postmenopausal women—a significant milestone for women’s sexual health.
How Addyi Works
Addyi (flibanserin) works by modulating serotonin receptors in the brain. Specifically, it acts as an agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors, while also affecting dopamine and norepinephrine levels. This neurochemical rebalancing aims to shift the brain toward greater sexual interest over time.
Addyi requires consistent daily use—typically for 4-8 weeks—before women notice meaningful changes in desire.
Understanding Addyi’s Usage and Considerations
Dosing: One 100mg tablet taken at bedtime, every night
Onset: Benefits typically emerge after 4-8 weeks of consistent use
Efficacy: Clinical trials demonstrated an average increase of approximately 0.5-1 satisfying sexual events per month compared to placebo. A significant percentage of women reported clinically meaningful benefits compared to those on placebo.
Side Effects: Common adverse effects include dizziness, somnolence, nausea, and fatigue. Approximately 13% of women in trials discontinued due to side effects.
Critical Consideration: Addyi carries an FDA boxed warning about hypotension and fainting when taken close in time with alcohol. To reduce risk, patients are advised to wait at least 2 hours after 1–2 standard drinks before taking Addyi at bedtime, or skip the dose if they’ve had 3+ drinks that evening—and after taking Addyi at bedtime, avoid alcohol until the following day.
Addyi is also contraindicated in women with hepatic impairment and those taking moderate or strong CYP3A4 inhibitors (certain antifungals, antibiotics, and other medications).
Introducing Libida™: The Dual-Pathway Approach to Desire
Libida™ represents a fundamentally different approach to female libido support. Designed for on-demand use, Libida™ is taken when intimacy is anticipated, with effects beginning within 45-60 minutes.
What makes Libida™ unique is its dual-pathway formulation. It’s the first women-first libido solution combining bremelanotide (the same FDA-approved active ingredient found in injectable Vyleesi) with oxytocin—addressing both the neurochemical desire spark and the emotional connection pathways that shape female arousal.
The Science Behind Libida’s Unique Formula
Bremelanotide activates melanocortin receptors (specifically MC4R) in the hypothalamus—a brain region central to sexual function. This activation enhances motivation, sexual thoughts, anticipation, and arousal. It’s a brain-acting peptide that works where desire originates.
Oxytocin, often called the “bonding hormone,” supports connection, closeness, and emotional readiness for intimacy. It activates pathways associated with trust, relaxation, and relational warmth. For many women, feeling emotionally safe and connected is inseparable from feeling desire—Libida™ addresses this dimension.
Together, these two pathways reflect how women’s sexuality actually works: a combination of neurochemical activation and emotional openness.
Why a Dual-Pathway Solution Matters
Female sexual response involves responsive desire—often triggered by emotional intimacy and context rather than spontaneous urges. A treatment addressing only neurotransmitters without supporting emotional connection may help some women, but leaves others feeling that something is still missing.
Libida™‘s combination approach was designed specifically with this understanding. The bremelanotide component provides the neurochemical push toward desire, while oxytocin supports the emotional softening that allows desire to flourish.
How Libida™ Works: Brain-First for Desire and Connection
Boosting Dopamine and Arousal with Bremelanotide
Bremelanotide works through the melanocortin system, a network of receptors and peptides involved in numerous physiological processes including sexual function. When bremelanotide binds to MC4R receptors in the hypothalamus, it triggers increased dopamine release—the neurotransmitter associated with motivation, reward, and wanting.
Clinical evidence for bremelanotide (studied as the injectable Vyleesi) shows:
- Increased sexual desire and arousal
- More satisfying sexual events
- Reduced distress related to low desire
- Restored sexual fantasies and responsiveness
The effects of bremelanotide can last up to 24 hours after administration, providing flexibility rather than requiring the moment to be precisely planned.
The Role of Oxytocin in Intimacy and Connection
Oxytocin is released naturally during positive social interactions, physical touch, and orgasm. It’s deeply involved in pair bonding, trust, and the sense of emotional safety that allows vulnerability.
By including oxytocin in Libida™’s formulation, the treatment supports the relational dimensions of sexuality. This may be particularly meaningful for women who love their partners but struggle to “get in the mood”—not because of neurochemical deficiency alone, but because the emotional bridge to intimacy feels harder to cross.
Libida™ vs. Addyi: Key Differences in Treatment Approach
Dosage and Timing
Libida™: A small sublingual tablet (lozenge) taken approximately 45-60 minutes before anticipated intimacy. No daily commitment required—use it when you want it.
Addyi: A daily oral tablet taken at bedtime, every night, regardless of whether sexual activity is anticipated. Benefits emerge after 4-8 weeks of consistent use.
Alcohol Considerations
Libida™: Clinical caution is advised, but there is no FDA contraindication against alcohol use.
Addyi: Carries an FDA boxed warning. Alcohol combined with Addyi can cause dangerous drops in blood pressure and fainting.
Mechanism of Action
Libida™: Works through two distinct pathways—melanocortin receptor activation (bremelanotide) for neurochemical desire and oxytocin receptor activation for emotional connection and bonding.
Addyi: Works through serotonin receptor modulation, affecting the balance of inhibitory and excitatory neurotransmitters over time.
Administration
Libida™: Sublingual tablet that dissolves under the tongue—no injections, no swallowing pills daily.
Addyi: Traditional oral tablet swallowed with water at bedtime.
Clinical Efficacy: What Can You Expect?
Evidence Supporting Libida’s Components
The bremelanotide component of Libida™ has been studied extensively in FDA trials for Vyleesi. Data showed significant improvements in desire and arousal, with women reporting more satisfying sexual experiences and reduced distress about their low libido.
Because Libida™ delivers bremelanotide via sublingual route rather than injection, it removes one of the primary barriers women cited with Vyleesi—the need for self-injection. The addition of oxytocin builds upon bremelanotide’s neurochemical effects by supporting the emotional dimension of desire.
Addyi’s Clinical Track Record
Addyi’s three pivotal trials enrolled over 2,000 women and demonstrated statistically significant improvements in desire, satisfying sexual events, and reduced distress compared to placebo.
The 10+ years of real-world prescribing data for Addyi provides substantial safety information.
Common Side Effects
Libida™: Based on the bremelanotide component, potential side effects include nausea, flushing, and headache. Libida™ should not be used during pregnancy, breastfeeding, or by women with uncontrolled hypertension or certain cardiovascular conditions.
Addyi: Dizziness, somnolence, nausea, and fatigue are most common. The alcohol interaction risk adds a layer of complexity to daily use.
Cost and Accessibility: Comparing Your Investment
Libida™ Pricing
Libida™ offers flexible pricing options:
- One-time purchase available
- Subscription options for ongoing use
- Estimated cost per use: approximately $8-10 per experience
- HSA/FSA eligible
Libida™ is accessed through Inner Balance’s telehealth platform, with board-certified physicians licensed in all 50 states providing prescriptions within 24-48 hours of completing the health assessment.
Addyi Pricing
- With insurance: Can be as low as $40 per year with good coverage
- Assistance programs: Available for cash-pay patients
- Costs vary based on insurance coverage
Who Is Each Treatment Best For?
Libida™ May Be Right For You If:
- Your desire feels muted, disconnected, or missing—even though you love your partner
- You’ve identified with thoughts like “my spark is gone” or “I never feel like it anymore”
- Your hormones are optimized but desire still feels flat
- You want on-demand flexibility rather than daily medication
- You prefer a sublingual tablet over injections or daily pills
- You drink alcohol socially and prefer treatment without strict restrictions
- You want a treatment addressing both neurochemical desire AND emotional connection
- You’re looking for a brain-first, non-hormonal approach that can complement existing hormone therapy
Addyi May Be Right For You If:
- You prefer an FDA-approved treatment with extensive published clinical data
- Your insurance covers Addyi well, making it highly affordable
- You’re comfortable with daily medication routines
- You don’t drink alcohol or can consistently avoid it around dosing
- You’re not taking CYP3A4 inhibitors or medications that interact
Libida™ and Hormonal Balance: A Complementary Approach
For many women, low libido coexists with broader hormone imbalance. Perimenopause and menopause bring declining estrogen and progesterone, which affect vaginal health, mood, sleep, and energy—all of which influence sexual desire. Conditions like PCOS and endometriosis create their own hormonal challenges that can dampen libido.
This is where Inner Balance’s comprehensive approach offers particular value. Oestra™, Inner Balance’s bioidentical hormone enrichment cream, addresses systemic hormonal symptoms through vaginal delivery—providing enhanced bioavailability compared to oral hormones while bypassing liver metabolism. Women report improvements in sleep, mood, energy, and libido when hormones are restored.
Some women optimize their hormones and still find desire elusive. The hormonal foundation may be solid, yet the neurological spark remains dim. This is precisely where Libida™ fits—as the “missing piece” for women whose desire needs more than hormone therapy alone.
Libida™ is non-hormonal and designed to be compatible with any hormonal status. It can be used on its own or alongside Oestra™ for women who want to address both their hormonal foundation and their brain’s desire pathways. This isn’t about replacing hormone therapy—it’s about building upon it when needed.
Making the Right Choice
Choosing between Libida™ and Addyi ultimately depends on your individual circumstances, preferences, and what’s causing your low desire.
Addyi offers FDA-approved validation backed by a decade of clinical data, with potential for excellent insurance coverage making it highly affordable for some women. Daily dosing builds steady-state medication levels over time.
Libida™ offers on-demand flexibility with a dual-pathway approach addressing both neurochemical desire and emotional connection. It provides the freedom to use treatment only when anticipated, with sublingual administration that’s convenient and injection-free.
Many women find that addressing their hormonal foundation first—through treatments like Oestra™—provides significant improvement in desire. For those who’ve optimized hormones but still feel their spark is missing, Libida™ can provide targeted neurological support without disrupting the hormonal balance you’ve achieved.
Inner Balance offers board-certified physician consultations to help determine whether Libida™, Oestra™, or both might be right for your specific situation. Because you deserve to feel like yourself again—including in the intimate dimensions of your life.
Libida™ is a brain-based libido booster for women – no hormones, meds, or injections. One dissolvable tablet to bring the spark back, on your terms.
HSA/FSA Eligible •
Free shipping • Cancel anytime
Frequently Asked Questions
Is Libida™ FDA-approved?
Libida™ contains bremelanotide, the same active ingredient that is FDA-approved in its injectable form (Vyleesi) for premenopausal women with HSDD. Libida™ is a compounded formulation combining bremelanotide with oxytocin, prescribed under clinician guidance. The sublingual delivery method removes the injection barrier while providing the proven melanocortin mechanism plus oxytocin’s bonding benefits.
Can I use Libida™ if I’m already on hormone replacement therapy?
Yes. Libida™ is non-hormonal and compatible with any hormonal status. Many women use it alongside hormone therapy like Oestra™—addressing their hormonal foundation through bioidentical hormone restoration while using Libida™ for targeted neurological desire support when needed. This complementary approach can be particularly effective for women whose desire lags even after hormones are optimized.
How quickly does Libida™ work, and how long do effects last?
Libida™ is taken approximately 45-60 minutes before anticipated intimacy. Effects begin within this timeframe and may last up to 24 hours. This provides flexibility—you don’t need to predict the exact moment, and the effects can extend across a romantic evening.
What are the main side effects to expect from each treatment?
For Libida™, based on its bremelanotide component, potential side effects include nausea, flushing, and headache. For Addyi, common side effects include dizziness, somnolence, nausea, and fatigue. Addyi also carries a boxed warning about interactions with alcohol, requiring lifestyle adjustments.
How does the cost of Libida™ compare to other options?
Libida™ has an estimated cost of approximately $8-10 per use, with subscription options available. It’s HSA/FSA eligible. Addyi can be highly affordable with excellent insurance coverage, or available through assistance programs for cash-pay patients. For women using treatment on-demand rather than daily, Libida™ often represents a cost-effective option since you’re paying only when you anticipate intimacy.
